Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 322

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 322
---
 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or
similar business combination with one or more businesses (a “business combination”).

Reverse Stock Split – On January
8, 2025, we effected a reverse stock split of our shares of common stock at a ratio of 1-for-100 (the “Reverse Stock Split”).
The Company’s common stock continued trading on Nasdaq on a post-split basis under the Company’s existing trading symbol,
“CERO.”

All of the Company’s historical share and
per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock
in these financial statements have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.

Business Combination Agreement - On June
6, 2023, CERo Therapeutics, Inc. (“Predecessor”), which was incorporated in Delaware on September 23, 2016, and based in
South San Francisco, California, entered into a Business Combination Agreement and Plan of Reorganization (the “BCA”) with
PBCE Merger Sub, Inc., a wholly-owned subsidiary of PBAX, and PBAX, with the surviving operating entity being named CERo Therapeutics
Holdings, Inc. (“Successor” or the “Company”), and such transaction, the “Merger”.

The Company is focused on genetically engineering
human immune cells to fight cancer. The Predecessor focused on developing the CERo therapeutic platform and had not yet begun clinical
development or product commercialization. The Company’s efforts will focus on continued product development, including clinical
development, to support regulatory approval to commercialize and subsequent product commercialization.

The BCA was amended on February 5, 2024 and again
on February 13, 2024. The Merger closed on February 14, 2024 (the “Closing”), at which time the following occurred:

| 1. | The outstanding shares                                                                                                                   
 of Predecessor’s Preferred Stock were converted into 44,155 shares of Common Stock, par value $0.0001 per share (the “Common             
 Stock”), valued at $21,635,926.                                                                                                          |
| 2. | The outstanding shares                                                                                                                   
 of Predecessor’s common stock were converted into 5,845 shares of Common Stock, valued at $2,864,074.                                    |
| 3. | Each holder of Predecess